Boost Cardiometabolic Health with ProLon: A Proven Path to Metabolic Renewal and Longevity
As healthcare practitioners dedicated to improving patient outcomes in metabolic and cardiovascular health, understanding and addressing the complex interplay between the heart and metabolism—known as cardiometabolic health—is essential. Cardiometabolic health encompasses a spectrum of biological processes and risk factors including blood lipid profiles, blood sugar regulation, inflammation, body composition, and overall metabolic function. These factors collectively influence the risk of heart disease, type 2 diabetes, stroke, and hypertension, which remain leading causes of morbidity and mortality globally.
At L-Nutra, we recognise that traditional approaches focusing only on isolated markers such as cholesterol or fasting glucose can miss the broader picture. That’s why we emphasise the use of comprehensive cardiometabolic assessments in clinical practice. These detailed blood panels provide in-depth insights that allow you to tailor interventions directly targeting your patients’ unique metabolic challenges. When combined with evidence-based nutritional therapeutics, such as our ProLon® Fasting Mimicking Diet (FMD), you can offer interventions that restore metabolic health while empowering patients with sustainable lifestyle strategies.
Scientific Rationale and Clinical Evidence Behind the Fasting Mimicking Diet
ProLon’s FMD is a patented, plant-based, low-calorie dietary program designed to mimic the physiological effects of fasting while still providing essential nutrients. Rather than complete food abstinence, a significant barrier for many patients, ProLon’s FMD facilitates fasting-like metabolic states through a carefully formulated nutritional regimen over five days. This approach activates key cellular pathways involved in renewal and repair, including autophagy and stem cell regeneration.
Extensive clinical research, much of which is led or supported by L-Nutra, has established compelling evidence for the FMD’s benefits in cardiometabolic health. Several randomised controlled trials have documented improvements after just three to six monthly cycles of ProLon’s FMD, including:
● Significant reductions in fasting blood glucose and insulin resistance, critical targets for patients with prediabetes and metabolic syndrome.
● Modest but meaningful decreases in LDL cholesterol and triglycerides, supporting cardiovascular risk reduction.
● Selective loss of visceral adipose tissue, the metabolically harmful fat depot linked to insulin resistance and inflammation, while preserving lean body mass.
● Reductions in systemic inflammatory markers such as C-reactive protein (CRP) and insulin-like growth factor 1 (IGF-1), both associated with aging and chronic disease risk.
● Improvements in HbA1c levels, reflecting better long-term glycemic control, particularly in individuals with type 2 diabetes.
●
These physiological shifts not only translate to improved biochemical profiles but also support patients’ overall vitality and longevity by addressing fundamental mechanisms of metabolic dysfunction and cellular aging.
Integration into Clinical Practice
For practitioners using ProLon in clinic settings, the FMD provides a practical, research-validated tool to complement comprehensive diagnostic strategies. When combined with cardiometabolic blood panels—covering lipid fractions, inflammatory markers, glucose regulation, and more—you can stage your patients’ risk precisely, customise intervention plans, and monitor progress objectively.
The structured nature of ProLon’s five-day programme also facilitates adherence, even in patients who have struggled with conventional dieting approaches. By offering a scientifically designed, nutrient-rich yet low-calorie regimen, patients experience the benefits of fasting physiology without the hurdles of complete fasting. This translates to high patient satisfaction, improved metabolic outcomes, and, importantly, long-term behavioural change when integrated into broader lifestyle counselling.
Empowering Healthcare Practitioners and Patients
We understand the challenges healthcare providers face in managing metabolic disease—frustration with limited patient progress, uncertainty in prolonged compliance, and the complexity of personalising nutrition advice. ProLon’s FMD, backed by rigorous science and designed for clinical use, can serve as a transformative adjunct in your therapeutic toolkit.
Patients often report feeling revitalised post-FMD cycles, with measurable improvements in energy, weight parameters, and lab markers reinforcing their motivation. As a practitioner, witnessing these tangible benefits helps deepen the therapeutic alliance and encourages sustained engagement.
L-Nutra’s Fasting Mimicking Diet, delivered through ProLon, represents a paradigm shift in nutritional intervention for cardiometabolic health. Grounded in robust scientific research and practical clinical application, ProLon offers healthcare practitioners an effective, safe, and patient-friendly fasting protocol to support metabolic restoration, reduce disease risk, and promote healthy aging.
By integrating detailed cardiometabolic testing with targeted FMD cycles, you equip your practice with tools to offer truly personalised precision nutrition solutions—empowering patients to take control of their health and build lasting cardiometabolic resilience.
As research evolves, L-Nutra remains committed to providing practitioners with ongoing education, resources, and clinical support necessary to harness the full potential of the Fasting Mimicking Diet in transforming patient care.
For more information on implementing ProLon and accessing clinical tools, please contact your L-Nutra representative. Together, let’s advance metabolic health and longevity for the patients and communities we serve.
Reference List
- Wei, M., Brandhorst, S., et al. (2017). Fasting‐Mimicking Diet and Risk Factors for Aging, Diabetes, Cancer and Cardiovascular Disease. Science Translational Medicine, 9(377), eaai8700.
A randomized controlled trial showing that periodic FMD cycles reduce IGF-1, CRP, blood pressure, LDL cholesterol, and abdominal fat while preserving lean mass. [PMCID: PMC6816332] - Brandhorst, S., et al. (2024). Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. Nature Communications.
Clinical evidence that three cycles of FMD lower insulin resistance, hepatic fat, inflammation markers, and biological age by 2.5 years independently of weight loss. [PMC article] - Valter Longo's Laboratory, USC Leonard Davis School of Gerontology (2024). Cycles of a fasting-mimicking diet reduce immune system aging, insulin resistance, and liver fat, supporting longevity. Nature Communications.
This study demonstrates the rejuvenation effects of FMD on metabolic and immune markers in humans. - ClinicalTrials.gov Identifier: NCT02158897. Multi-cycle ProLon Diet Study.
A clinical trial assessing the impact of 5-day monthly FMD cycles on adult subjects’ metabolic health. - Micarelli, A., et al. (2025). Chemosensory and cardiometabolic improvements after a 5-day fasting-mimicking diet. Scientific Reports.
Research on ProLon’s effects on cardiometabolic variables and patient outcomes.
American Association for Cancer Research (2021). “Fasting-mimicking” Diet Found Safe and Potentially Helpful to Cancer Patients.
Highlights safety and beneficial biological effects of short-term FMD in clinical contexts.